For example, Herceptin is used in patients with female breast cancer with HER-2 expression, Imatinib targets the BCR/ABL fusion gene in chronic myeloid leukemia, Vemurafenib targets BRAF mutations in melanoma, and Gleevec inhibits tyrosine kinase activity in chronic myeloid leukemias. This evidence concerns the gene BRAF and chronic myelogenous leukemia, BCR-ABL1 positive.